Inflammation helps start bone repair, but pain relief is not proof of faster healing. Learn why NSAID findings need injury-specific interpretation.
0.65% was the one-year rate of surgery for malunion or nonunion among patients prescribed NSAIDs in a 2026 fracture-surgery cohort. That number becomes meaningful only when the comparison group and the outcome are clear. It is a useful starting point for understanding why inflammation and anti-inflammatory medicine resist simple good-or-bad labels.
The familiar belief is that inflammation is an unwanted obstacle after injury. In that view, reducing it should ease symptoms and help the tissue heal faster. This combines two different goals: feeling better and repairing damaged tissue.
It is an understandable way to think about recovery. Less pain can seem like a clear sign that everything underneath is improving. But symptom relief and tissue healing are not interchangeable outcomes.
The opposite claim is also too broad: inflammation is necessary, so reducing it must interfere with healing. That turns a useful biological insight into a rule about every injury and every treatment.
Neither position gives enough attention to the tissue involved or the outcome being measured. Wanting relief is reasonable. The assumption worth questioning is that reducing inflammation must either improve all aspects of recovery or harm them all.
A review of bone regeneration describes early inflammation as part of the repair process. It helps establish the initial injury environment and recruit immune cells. It also supports the clearance of damaged material and starts signals involved in healing.
The same review describes inflammation, repair and remodeling as overlapping phases. These are not separate boxes that the body moves through on a fixed schedule. The biology is more connected than a simple sequence might suggest.
This changes the question. Instead of asking whether inflammation is always harmful, it is more useful to ask how the response supports repair and moves toward resolution. The goal is not to produce as much inflammation as possible.
A narrative review of ligament healing provides the other side of that picture. It notes that persistent inflammation can impair regeneration. Together, these reviews support a coordinated response rather than either complete suppression or unchecked inflammation.
How that biology translates into a medication decision remains context-dependent. Understanding why an inflammatory response exists does not by itself settle whether a particular person should receive an anti-inflammatory medicine.
It also helps to keep tissue repair separate from the return of physical function. A claim about one part of recovery should be judged by evidence about that part, rather than treated as a verdict on the whole process.
The strongest way to assess an inflammation claim is to look at what researchers actually studied. A biological review and a study of surgical outcomes contribute different kinds of information. Reading them together is useful, provided those roles stay clear.
The 2026 study published in the European Journal of Orthopaedic Surgery & Traumatology examined people undergoing distal-radius-fracture surgery. It used a propensity-matched cohort to compare patients prescribed NSAIDs with matched controls who were not prescribed them.
Its primary outcome was surgery for malunion or nonunion at one year. The reported rates were 0.65% among patients prescribed NSAIDs and 0.55% among matched controls. The investigators reported no statistically significant difference in that outcome.
The authors also reported small absolute differences of under 1% in infection and revision outcomes. They advised weighing the findings against individual risk factors. Those additional outcomes belong in the interpretation alongside the primary result.
The important distinction is between the question studied and the much broader claim that anti-inflammatory medicines necessarily prevent bone healing. The cohort gives evidence about a defined surgical setting. Its findings should be described in those terms.
The cohort paper's discussion also summarizes a randomized trial involving 95 patients with displaced distal radius fractures. That trial compared ibuprofen with placebo. It reported no differences in measures of bone density, callus or bone turnover at follow-up.
This adds another type of evidence to the discussion. The cohort assessed a further-surgery outcome, while the trial assessed bone-related measures. These findings are useful counterweights to blanket claims about harm, but they should not be combined into a claim that researchers measured every aspect of recovery.
The fracture-surgery cohort was observational. Matching groups does not establish that NSAID prescriptions caused the outcomes reported. Its findings apply to the population and outcomes studied rather than every fracture or operation.
Its primary outcome was further surgery for malunion or nonunion. That is not a measure of every aspect of healing or return to activity. A finding of no significant difference also does not prove that all NSAIDs, doses and durations have the same effects.
The smaller randomized trial is described here through the cohort paper's discussion. Its findings concern the measures assessed in that particular fracture group. It should not be presented as a universal medication rule.
The reviews have a different boundary. They explain repair biology and proposed approaches rather than establish a treatment plan for an individual patient. The ligament review's proposed treatment approaches are preclinical, not established human therapies.
The practical message is not to choose a side in an argument about whether inflammation is good or bad. It is to connect symptom relief with the broader recovery plan. Medication decisions belong in a discussion of individual risks and benefits with the treating clinician.
A useful first question is what a treatment is intended to achieve. Easing pain is a different goal from changing tissue repair. A benefit for the first goal should not automatically be presented as evidence for the second.
That distinction does not make comfort unimportant. It simply keeps the claim accurate. Less pain or easier movement can be valuable without proving that the tissue has healed faster.
Questions that can help organize a clinical conversation include:
These questions are a way to understand the reasoning behind care. They are not a schedule for starting or stopping medication. Any change to a personal medication plan needs a conversation with the qualified professional responsible for that care.
The same approach helps when reading online recovery claims. First identify the promised outcome. Does the claim concern pain, a measure of tissue repair or a return to a particular activity?
Next, look for evidence that actually measured that outcome. A study reporting fewer symptoms answers a symptom question. A study reporting further surgery answers a different question. Neither result should silently become a claim about everything recovery involves.
This matters when thinking about the physical abilities involved in rebuilding activity. A comfortable movement and readiness for a demanding activity are different claims. Evidence about the first should not be stretched into proof of the second.
For readers facing conflicting advice, this creates a calmer way to assess a headline. There is no need to decide that inflammation is either an enemy or something that should never be reduced. The more useful task is to understand the goal of care and how the evidence relates to it.
Inflammation has a role in starting bone repair. Persistent inflammation can also become a problem, as the ligament review describes. Those findings support a coordinated response that moves toward repair rather than a rule to eliminate or maximize inflammation.
The fracture evidence also argues against blanket statements about NSAIDs and healing. The clearest takeaway is to keep the outcomes separate: symptom relief matters, but it is not proof of faster tissue repair. Decisions about medication and rehabilitation are best grounded in the specific injury and a clinician's assessment of individual risks and benefits.
Treating inflammation as an enemy turns a complex recovery process into an overly simple rule; ReboundBody keeps its explanations tied to evidence and realistic limits. For active adults facing conflicting treatment claims after injury or surgery, its independent articles put rehabilitation research into context for more informed conversations with qualified healthcare professionals.
Follow ReboundBody for practical articles on injury recovery, rehabilitation, mobility and rebuilding strength. New posts turn research into clear ideas for the road back to activity after injury or surgery.
Read practical guidance on injury recovery, rehabilitation, mobility and rebuilding strength as you work your way back to activity.
Explore Resources